Literature DB >> 15292153

Escherichia coli serogroup O107/O117 lipopolysaccharide binds and neutralizes Shiga toxin 2.

Shantini D Gamage1, Colleen M McGannon, Alison A Weiss.   

Abstract

The AB(5) toxin Shiga toxin 2 (Stx2) has been implicated as a major virulence factor of Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains in the progression of intestinal disease to more severe systemic complications. Here, we demonstrate that supernatant from a normal E. coli isolate, FI-29, neutralizes the effect of Stx2, but not the related Stx1, on Vero cells. Biochemical characterization of the neutralizing activity identified the lipopolysaccharide (LPS) of FI-29, a serogroup O107/O117 strain, as the toxin-neutralizing component. LPSs from FI-29 as well as from type strains E. coli O107 and E. coli O117 were able bind Stx2 but not Stx1, indicating that the mechanism of toxin neutralization may involve inhibition of the interaction between Stx2 and the Gb(3) receptor on Vero cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292153      PMCID: PMC490921          DOI: 10.1128/JB.186.16.5506-5512.2004

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  42 in total

1.  The structure of the O-specific polysaccharide of Escherichia coli O117:K98:H4.

Authors:  M R Leslie; H Parolis; L A Parolis
Journal:  Carbohydr Res       Date:  2000-01-12       Impact factor: 2.104

2.  Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands.

Authors:  P I Kitov; J M Sadowska; G Mulvey; G D Armstrong; H Ling; N S Pannu; R J Read; D R Bundle
Journal:  Nature       Date:  2000-02-10       Impact factor: 49.962

3.  A mutant Shiga-like toxin IIe bound to its receptor Gb(3): structure of a group II Shiga-like toxin with altered binding specificity.

Authors:  H Ling; N S Pannu; A Boodhoo; G D Armstrong; C G Clark; J L Brunton; R J Read
Journal:  Structure       Date:  2000-03-15       Impact factor: 5.006

4.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.

Authors:  C S Wong; S Jelacic; R L Habeeb; S L Watkins; P I Tarr
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

Review 5.  Glycolipid receptors for verotoxin and Helicobacter pylori: role in pathology.

Authors:  C A Lingwood
Journal:  Biochim Biophys Acta       Date:  1999-10-08

6.  Role for a phage promoter in Shiga toxin 2 expression from a pathogenic Escherichia coli strain.

Authors:  P L Wagner; M N Neely; X Zhang; D W Acheson; M K Waldor; D I Friedman
Journal:  J Bacteriol       Date:  2001-03       Impact factor: 3.490

7.  Distribution of core oligosaccharide types in lipopolysaccharides from Escherichia coli.

Authors:  K Amor; D E Heinrichs; E Frirdich; K Ziebell; R P Johnson; C Whitfield
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

8.  Toxin gene expression by shiga toxin-producing Escherichia coli: the role of antibiotics and the bacterial SOS response.

Authors:  P T Kimmitt; C R Harwood; M R Barer
Journal:  Emerg Infect Dis       Date:  2000 Sep-Oct       Impact factor: 6.883

Review 9.  Food-related illness and death in the United States.

Authors:  P S Mead; L Slutsker; V Dietz; L F McCaig; J S Bresee; C Shapiro; P M Griffin; R V Tauxe
Journal:  Emerg Infect Dis       Date:  1999 Sep-Oct       Impact factor: 6.883

10.  A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans.

Authors:  A W Paton; R Morona; J C Paton
Journal:  Nat Med       Date:  2000-03       Impact factor: 53.440

View more
  9 in total

Review 1.  Virulence and immunomodulatory roles of bacterial outer membrane vesicles.

Authors:  Terri N Ellis; Meta J Kuehn
Journal:  Microbiol Mol Biol Rev       Date:  2010-03       Impact factor: 11.056

2.  Different classes of antibiotics differentially influence shiga toxin production.

Authors:  Colleen Marie McGannon; Cynthia Ann Fuller; Alison Ann Weiss
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

Review 3.  Shiga Toxin (Stx) Classification, Structure, and Function.

Authors:  Angela R Melton-Celsa
Journal:  Microbiol Spectr       Date:  2014-08

4.  Comparative analysis of the abilities of Shiga toxins 1 and 2 to bind to and influence neutrophil apoptosis.

Authors:  Michael J Flagler; Jane E Strasser; Claudia L Chalk; Alison A Weiss
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

5.  Comparison of binding platforms yields insights into receptor binding differences between shiga toxins 1 and 2.

Authors:  Michael J Flagler; Sujit S Mahajan; Ashish A Kulkarni; Suri S Iyer; Alison A Weiss
Journal:  Biochemistry       Date:  2010-03-02       Impact factor: 3.162

6.  Commensal bacteria influence Escherichia coli O157:H7 persistence and Shiga toxin production in the mouse intestine.

Authors:  Shantini D Gamage; Angela K Patton; Jane E Strasser; Claudia L Chalk; Alison A Weiss
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

7.  Binding of Pk-trisaccharide analogs of globotriaosylceramide to Shiga toxin variants.

Authors:  Hailemichael O Yosief; Suri S Iyer; Alison A Weiss
Journal:  Infect Immun       Date:  2013-05-20       Impact factor: 3.441

8.  The inhibitory effect of colloidal bismuth hydroxide gel on Escherichia coli O157:H7 and on the activity of Shiga toxins.

Authors:  Tomás Subils; Cecilia Casabonne; Claudia Balagué
Journal:  BMC Res Notes       Date:  2014-12-04

Review 9.  Metabolism of Glycosphingolipids and Their Role in the Pathophysiology of Lysosomal Storage Disorders.

Authors:  Alex E Ryckman; Inka Brockhausen; Jagdeep S Walia
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.